Phaseline

Targets › ADI1

ADI1 (Acireductone dioxygenase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2027.

Catalyzes 2 different reactions between oxygen and the acireductone 1,2-dihydroxy-3-keto-5-methylthiopentene (DHK-MTPene) depending upon the metal bound in the active site (By similarity). Fe-containing acireductone dioxygenase (Fe-ARD) produces formate and 2-keto-4-methylthiobutyrate (KMTB), the alpha-ketoacid precursor of methionine in the methionine recycle pathway. (UniProt, Q9BV57)

Open in Phaseline: the race on ADI1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chongqing Peg-Bio BiopharmPA5
Pegylated Arginine Deiminase Dimer
ADI1Phase 1Advanced Solid TumorsFeb 2027

Conditions

Advanced Solid Tumors (1)

Modalities

protein or peptide (1)

Companies

Chongqing Peg-Bio Biopharm (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.